Compare BIO-TECHNE Corp (TECH) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Xylem, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Xylem, Inc. trades at $107.97 (market cap $25.41B). The key difference: Xylem, Inc. is far larger — about 2.2× BIO-TECHNE Corp's market cap, and Xylem, Inc. pays the higher dividend (1.58%). Which is the better fit depends on your goals.
| TECH | XYL | |
|---|---|---|
Market Cap | $11.34B | $25.41B |
Sector | Health | Industrials |
52-Week High | $72.48 | $152.95 |
52-Week Low | $43.31 | $105.69 |
Enterprise Value | $11.36B | $27.18B |
Dividend Yield | 0.44% | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
XYL trades at $108.81, up 2.95% today, with a bearish technical signal but strong fundamentals including consistent earnings beats and a 10.59% net margin. Recent news highlights strategic acquisitions, a new CFO appointment, and a dividend declaration, supporting growth in water technology sectors. The stock shows resilience with revenue growth from $5.5B in 2022 to $9.04B in 2025, though it faces near-term resistance.
Outlook is cautiously optimistic with a consensus price target of $152.29 implying 40% upside, driven by margin expansion and AI-driven demand. Risks include execution of acquisitions and market volatility, but analyst sentiment leans buy/hold with low sell ratings. The stock presents a value opportunity for long-term investors focused on sustainable water solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
